The PI3K/AKT Pathway as a Target for Cancer Treatment.

By Ingrid A. Mayer, Carlos L. Arteaga. Annual Review of Medicine, 2016

772 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/347b8cefab0222e7235959f9a62ad26be3d0caa1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Fruman

In Molecular Biology

1. Gautam Sethi
2. D. Fruman

Citations in the corpus

• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “In cancer cells, mutations [23] and/or gene amplifications in AKT [116], or mutations upstream genes in the PAM pathway, especially PI3K genes [15] and PTEN [148], can potentially result in AKT-induced overactivation of mTORC1, leading to increased cell survival, growth, proliferation, and metabolis”
• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “The current pan-PI3K and mTOR inhibitors mainly include SF1126, dactolisib (Bez235), voxtalisib (XL765) and GSK1059615.(30) Although this type of inhibitor is less specific than isotype-specific inhibitors, it has the potential to treat a variety of tumors with a wide range of genetic abnormalities;”